Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.

Published

Journal Article

The Stand Up 2 Cancer/Prostate Cancer Foundation-funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.

Full Text

Duke Authors

Cited Authors

  • Aggarwal, R; Beer, TM; Gleave, M; Stuart, JM; Rettig, M; Evans, CP; Youngren, J; Alumkal, JJ; Huang, J; Thomas, G; Witte, O; Small, EJ

Published Date

  • December 2016

Published In

Volume / Issue

  • 2 / 5

Start / End Page

  • 469 - 471

PubMed ID

  • 28723508

Pubmed Central ID

  • 28723508

Electronic International Standard Serial Number (EISSN)

  • 2405-4569

Digital Object Identifier (DOI)

  • 10.1016/j.euf.2016.10.011

Language

  • eng

Conference Location

  • Netherlands